Conditions: Plaque-type Psoriasis
Keywords: Psoriasis Moderate to Severe Plaque-type Psoriasis Skin condition skin disease itching condition psoriasis vulgaris relapsing/remitting psoriasis immune-mediated systemic disease skin lesions red skin lesions scaly patches papules plaques itching
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 182
Healthy volunteers: no

Brief summary:
The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.

Detailed description:

Arms:
arm 1: Subjects who were in placebo at Week 52 cannot continue in the extension treatment period arm 2: After the data base lock of week 52 data has been performed, subjects received secukinumab 150 mg treatment as open label for the remainder of the extension treatment period. arm 3: After the data base lock of week 52 data has been performed, subjects received secukinumab 300 mg treatment as open label for the remainder of the extension treatment period.

Interventions: intervention 1: Placebo intervention 2: Secukinumab 150mg intervention 3: Secukinumab 300mg
Intervention descriptions: intervention 1: 2 injections of placebo to secukinumab 150mg per dose intervention 2: Secukinumab 150mg: 1 injection of 150 mg secukinumab and 1 injection of placebo to secukinumab 150mg per dose. After Week 52 database lock, study is open label so only 1 injection of secukinumab 150mg per dose were administered intervention 3: Secukinumab 300mg (2 injections of 150mg secukinumab per dose)

Protocol document: